Malone Sara, Counts Lara, Zabotka Luke, Williams Anneliese, Loecher Nele, Wynja Kayla, Bryan Gemma, Tanner Robin, Cáceres-Serrano Ana, Ferrara Gia, Fuentes Lucia, Bilbeisi Tharwa, Maheu Marissa, Oelkers Benjamin K, Ogwo Muna, Yaeger Lauren, Agulnik Asya, Graetz Dylan
School of Public Health, Washington University in St. Louis, St. Louis, MO, USA.
Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, USA.
EClinicalMedicine. 2025 Jul 24;86:103360. doi: 10.1016/j.eclinm.2025.103360. eCollection 2025 Aug.
Stigma experienced by individuals with disease is a barrier to health-seeking behaviors and outcomes. Our aim was to systematically review how stigma has been defined and measured and identify gaps in approaches to measurement and intervention.
A systematic review was conducted following PRISMA guidelines. Databases were searched for stigma measurement in health through July 2024. 8123 citations were screened. Data on definitions, measurement, psychometrics, and interventions were extracted. PROSPERO: CRD42023433176.
We identified 2267 studies (2605 tools) from 101 countries. 396 (15.2%) tools focused on development and 2369 (91.0%) applied tools. Most tools assessed adults (77.2%). Over 750 stigma tools were identified; many tools were adapted (n = 674) or shortened (n = 446). 117 studies reported effective interventions, primarily in adults. Key gaps included lack of consensus on definitions, limited pediatric-focused research, and insufficient attention to structural drivers of stigma.
This review calls for standardized, context-sensitive stigma measurement and interventions applicable across conditions and settings. Addressing these gaps is crucial to reducing the global burden of stigma and enhancing health outcomes. Future research should focus on unified conceptual approaches and definitions to develop globally adaptable tools and scalable interventions that address both the experiences and structural drivers of stigma.
Components for the programs involved in this work have been funded by St. Jude Children's Research Hospital, the National Cancer Institute (3POCA021765-44S2), the American Lebanese Syrian Associated Charities, and Siteman Cancer Center. The views in this paper are those of the authors and don't necessarily reflect the funding agencies. The funding agencies were not involved in the writing or submitting of this work.
患有疾病的个体所经历的污名化是寻求健康行为和结果的障碍。我们的目的是系统回顾污名化是如何被定义和测量的,并确定测量和干预方法中的差距。
按照PRISMA指南进行系统回顾。检索数据库以获取截至2024年7月的健康领域污名化测量相关文献。共筛选了8123条引用文献。提取了关于定义、测量、心理测量学和干预措施的数据。国际前瞻性系统评价注册库(PROSPERO)登记号:CRD42023433176。
我们从101个国家识别出2267项研究(2605种工具)。396种(15.2%)工具侧重于开发,2369种(91.0%)为应用工具。大多数工具评估的是成年人(77.2%)。识别出750多种污名化工具;许多工具是改编的(n = 674)或缩短的(n = 446)。117项研究报告了有效的干预措施,主要针对成年人。主要差距包括定义缺乏共识、针对儿童的研究有限以及对污名化的结构性驱动因素关注不足。
本综述呼吁采用标准化、因地制宜的污名化测量和干预措施,适用于各种情况和环境。解决这些差距对于减轻全球污名化负担和改善健康结果至关重要。未来的研究应侧重于统一的概念方法和定义,以开发全球适用的工具和可扩展的干预措施,解决污名化的经历和结构性驱动因素。
参与这项工作的项目组成部分由圣裘德儿童研究医院、美国国立癌症研究所(3POCA021765 - 44S2)、美国黎巴嫩叙利亚联合慈善机构和西曼癌症中心资助。本文中的观点仅代表作者,不一定反映资助机构的观点。资助机构未参与本文的撰写或提交工作。